Novartis (VTX:NOVN) Given a CHF 79 Price Target by BNP Paribas Analysts

BNP Paribas set a CHF 79 price target on Novartis (VTX:NOVN) in a research report sent to investors on Tuesday, September 11th. The firm currently has a neutral rating on the stock.

A number of other research analysts have also issued reports on NOVN. Credit Suisse Group set a CHF 80 target price on shares of Novartis and gave the company a neutral rating in a report on Monday, May 28th. HSBC set a CHF 79 target price on shares of Novartis and gave the company a neutral rating in a report on Tuesday, May 29th. JPMorgan Chase & Co. set a CHF 84 price objective on shares of Novartis and gave the stock a neutral rating in a report on Monday, June 4th. Barclays set a CHF 70 price objective on shares of Novartis and gave the stock a sell rating in a report on Monday, June 18th. Finally, Deutsche Bank set a CHF 89 price objective on shares of Novartis and gave the stock a neutral rating in a report on Wednesday, June 27th. Eleven equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Novartis presently has a consensus rating of Hold and an average price target of CHF 88.86.

VTX:NOVN traded up CHF 0.34 on Tuesday, reaching CHF 78.38. The stock had a trading volume of 11,210,000 shares, compared to its average volume of 5,980,000. Novartis has a 12-month low of CHF 72.45 and a 12-month high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Read More: Do closed-end mutual funds pay dividends?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply